Jinyu Bio-technology Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Jinyu Bio-technology has a total shareholder equity of CN¥5.5B and total debt of CN¥1.2M, which brings its debt-to-equity ratio to 0.02%. Its total assets and total liabilities are CN¥6.9B and CN¥1.4B respectively. Jinyu Bio-technology's EBIT is CN¥142.2M making its interest coverage ratio -9.4. It has cash and short-term investments of CN¥1.3B.
Anahtar bilgiler
0.02%
Borç/özkaynak oranı
CN¥1.15m
Borç
| Faiz karşılama oranı | -9.4x |
| Nakit | CN¥1.31b |
| Eşitlik | CN¥5.55b |
| Toplam yükümlülükler | CN¥1.35b |
| Toplam varlıklar | CN¥6.90b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
The Consensus EPS Estimates For Jinyu Bio-technology Co., Ltd. (SHSE:600201) Just Fell Dramatically
Sep 04
Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Sep 02Why We're Not Concerned Yet About Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) 25% Share Price Plunge
Jun 16Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Are Reducing Their Forecasts For This Year
Apr 30There's Reason For Concern Over Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Price
Mar 21Does This Valuation Of Jinyu Bio-technology Co., Ltd. (SHSE:600201) Imply Investors Are Overpaying?
Feb 28Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600201's short term assets (CN¥2.4B) exceed its short term liabilities (CN¥693.7M).
Uzun Vadeli Yükümlülükler: 600201's short term assets (CN¥2.4B) exceed its long term liabilities (CN¥660.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600201 has more cash than its total debt.
Borcun Azaltılması: 600201's debt to equity ratio has reduced from 1.1% to 0.02% over the past 5 years.
Borç Kapsamı: 600201's debt is well covered by operating cash flow (28697%).
Faiz Kapsamı: 600201 earns more interest than it pays, so coverage of interest payments is not a concern.